Empliciti(elotuzumab)
Empliciti (elotuzumab) is an antibody pharmaceutical. Elotuzumab was first approved as Empliciti on 2015-11-30. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against SLAM family member 7.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Empliciti
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Elotuzumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Empliciti | elotuzumab | Bristol Myers Squibb | N-761035 RX | 2015-11-30 | 2 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| empliciti | Biologic Licensing Application | 2022-03-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| multiple myeloma | — | D009101 | C90.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
elotuzumab, Empliciti, Bristol-Myers Squibb Company | |||
| 2025-11-06 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9176 | Injection, elotuzumab, 1 mg |
Clinical
Clinical Trials
73 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 18 | 36 | 13 | — | 8 | 68 |
| Plasma cell neoplasms | D054219 | — | — | 11 | 13 | 7 | — | 8 | 36 |
| Lymphoma | D008223 | — | C85.9 | 1 | — | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 3 | 3 | — | — | — | 4 |
| Hematologic neoplasms | D019337 | — | — | — | 2 | — | — | — | 2 |
| Smoldering multiple myeloma | D000075122 | — | — | — | 2 | — | — | — | 2 |
| Plasma cell leukemia | D007952 | — | C90.1 | — | 1 | — | — | — | 1 |
| Essential thrombocythemia | D013920 | — | D47.3 | — | 1 | — | — | — | 1 |
| Polycythemia vera | D011087 | — | D45 | — | 1 | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | — | 1 | — | — | — | 1 |
| Polycythemia | D011086 | EFO_0005804 | D75.1 | — | 1 | — | — | — | 1 |
| Immunoglobulin light-chain amyloidosis | D000075363 | — | — | — | 1 | — | — | — | 1 |
| Amyloidosis | D000686 | EFO_1001875 | E85 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
| Follicular lymphoma | D008224 | — | C82 | 1 | — | — | — | — | 1 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | — | — | — | — | 1 |
| Waldenstrom macroglobulinemia | D008258 | — | C88.0 | 1 | — | — | — | — | 1 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | — | — | — | — | 1 |
| B-cell lymphoma | D016393 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Elotuzumab |
| INN | elotuzumab |
| Description | Elotuzumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743010 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06317 |
| UNII ID | 1351PE5UGS (ChemIDplus, GSRS) |
Target
Agency Approved
SLAMF7
SLAMF7
Organism
Homo sapiens
Gene name
SLAMF7
Gene synonyms
CS1
NCBI Gene ID
Protein name
SLAM family member 7
Protein synonyms
19A24 protein, CD2 subset 1, CD2-like receptor activating cytotoxic cells, CD2-like receptor-activating cytotoxic cells, CD319, CRACC, Membrane protein FOAP-12, Novel Ly9, novel LY9 (lymphocyte antigen 9) like protein, Protein 19A
Uniprot ID
Mouse ortholog
Slamf7 (75345)
SLAM family member 7 (Q8BHK6)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Empliciti – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,569 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,594 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use